Shares in Israeli pharamaceutical giant Teva rose half a percent in Monday trading on the Tel Aviv Stock Exchange.
The small gain came after double-digit losses on Sunday, after Mylan NV won United States approval to sell cheaper versions of Teva's multiple-sclerosis treatment Copaxone.